Theravance Uses Organ-Selective R&D To Advance GI, Pulmonary Candidates

 
• By Joseph Haas
Back view image of young businessman standing against business sketch
Theravance expects 2021 to be a year of advancement for its pipeline

More from Business

More from Scrip